Clinical Trial Update: Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing safety, tolerability, and preliminary efficacy of CJRB-101 in combination with pembrolizumab in selected advanced or metastatic cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• CJRB-101
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: CJ Bioscience, Inc. | Conditions: NSCLC, HNSCC | Phase 1, Phase 2 | Status: RECRUITING